•
PR
PROK
ProKidney Corp. Class A Ordinary Shares
polygonBIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
--
Price Chart
Market Cap
302.91M
Volume
1.24M
52W High
$7.13
52W Low
$0.46
Open
$2.15
Prev Close
$2.14
Day Range
2.06 - 2.20
About ProKidney Corp. Class A Ordinary Shares
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
Latest News
ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025
GlobeNewswire Inc.•Nov 6
Play Likely Earnings Beat With 3 Top-Ranked Stocks
Zacks Investment Research•Jun 21
ProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering
GlobeNewswire Inc.•Jun 12
ProKidney Announces Proposed $125 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering
GlobeNewswire Inc.•Jun 10
ProKidney Announces Positive Interim REGEN-007 Phase 2 Trial Data and Provides Clinical and Operational Updates
GlobeNewswire Inc.•Jun 10
ProKidney Reports Business Updates and First Quarter 2024 Financial Results
GlobeNewswire Inc.•May 10
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Benzinga•Apr 15
ProKidney Announces Key Leadership Appointments Strengthening Clinical and Technical Operations
GlobeNewswire Inc.•Mar 25